Investors Purchase High Volume of Call Options on SELLAS Life Sciences Group (NASDAQ:SLS)

Posted by Geri Gentry on Jul 13th, 2026

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS – Get Free Report) was the target of unusually large options trading on Monday. Stock traders bought 105,817 call options on the stock. This is an increase of 242% compared to the typical daily volume of 30,935 call options.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in SLS. Vanguard Group Inc. lifted its position in SELLAS Life Sciences Group by 2.8% during the third quarter. Vanguard Group Inc. now owns 6,839,905 shares of the company’s stock valued at $11,012,000 after purchasing an additional 185,106 shares during the period. Anson Funds Management LP grew its position in SELLAS Life Sciences Group by 2,093.8% in the 3rd quarter. Anson Funds Management LP now owns 6,032,938 shares of the company’s stock worth $9,713,000 after purchasing an additional 5,757,938 shares during the period. Geode Capital Management LLC raised its stake in SELLAS Life Sciences Group by 35.9% during the 4th quarter. Geode Capital Management LLC now owns 3,077,337 shares of the company’s stock valued at $11,604,000 after buying an additional 812,953 shares during the last quarter. Marshall Wace LLP raised its stake in SELLAS Life Sciences Group by 23,550.0% during the 2nd quarter. Marshall Wace LLP now owns 2,715,489 shares of the company’s stock valued at $5,947,000 after buying an additional 2,704,007 shares during the last quarter. Finally, State Street Corp lifted its holdings in shares of SELLAS Life Sciences Group by 60.8% during the 4th quarter. State Street Corp now owns 2,188,171 shares of the company’s stock valued at $8,249,000 after buying an additional 827,257 shares during the period. 17.38% of the stock is owned by hedge funds and other institutional investors.

SELLAS Life Sciences Group Stock Performance

Shares of SLS stock traded down $0.30 during mid-day trading on Monday, hitting $12.46. The company’s stock had a trading volume of 3,336,828 shares, compared to its average volume of 8,584,046. The stock has a market cap of $2.45 billion, a price-to-earnings ratio of -54.20 and a beta of 2.42. SELLAS Life Sciences Group has a 52-week low of $1.39 and a 52-week high of $15.88. The business has a 50-day moving average price of $8.99 and a 200 day moving average price of $6.02.

SELLAS Life Sciences Group (NASDAQ:SLS – Get Free Report) last released its quarterly earnings data on Tuesday, May 12th. The company reported ($0.05) EPS for the quarter, beating the consensus estimate of ($0.06) by $0.01.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on SLS shares. Weiss Ratings restated a “sell (d-)” rating on shares of SELLAS Life Sciences Group in a report on Tuesday, April 21st. Alliance Global Partners reiterated a “buy” rating on shares of SELLAS Life Sciences Group in a research note on Monday, July 6th. Two research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, SELLAS Life Sciences Group has an average rating of “Hold” and an average price target of $10.00.

Get Our Latest Stock Analysis on SLS

SELLAS Life Sciences Group Company Profile

(Get Free Report)

SELLAS Life Sciences Group, Inc is a clinical-stage biopharmaceutical company focused on the development of active cellular immunotherapies for cancer. Headquartered in Waltham, Massachusetts, SELLAS specializes in targeting the Wilms’ tumor 1 (WT1) antigen, a protein commonly overexpressed in a range of hematologic and solid tumors. Since its founding, the company has built a pipeline around the use of peptide-based vaccines designed to train the patient’s own immune system to recognize and attack WT1-positive cancer cells.

The company’s lead product candidate, galinpepimut-S (GPS), is an investigational multi-peptide vaccine directed against WT1.